Voya Investment Management LLC Has $8.24 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Voya Investment Management LLC raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 398.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 273,739 shares of the biopharmaceutical company’s stock after buying an additional 218,766 shares during the quarter. Voya Investment Management LLC owned 0.18% of TG Therapeutics worth $8,240,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Penn Capital Management Company LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $10,577,000. Syon Capital LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $276,000. Price T Rowe Associates Inc. MD grew its holdings in TG Therapeutics by 264.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 297,101 shares of the biopharmaceutical company’s stock valued at $8,944,000 after buying an additional 215,601 shares during the last quarter. State of Tennessee Department of Treasury grew its holdings in TG Therapeutics by 28.4% in the 4th quarter. State of Tennessee Department of Treasury now owns 59,883 shares of the biopharmaceutical company’s stock valued at $1,802,000 after buying an additional 13,228 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in TG Therapeutics by 937.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 32,498 shares of the biopharmaceutical company’s stock valued at $978,000 after buying an additional 29,366 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $43.86 on Wednesday. The stock’s fifty day simple moving average is $37.66 and its 200 day simple moving average is $32.81. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market cap of $6.96 billion, a price-to-earnings ratio of -438.56 and a beta of 2.14. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.98.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TGTX. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.